Q1 2026 STAAR Surgical Co Earnings Call Transcript
Key Points
- Staar Surgical Co (STAA) reported strong net sales growth of 119.6% year over year, driven by significant performance in China and double-digit growth in the Americas.
- The company surpassed a significant milestone by selling over 4 million ICLs globally, indicating strong market demand and adoption.
- Staar Surgical Co (STAA) achieved a gross profit margin of 73.6%, up from 65.8% in the prior year, due to improved manufacturing efficiencies and cost reductions.
- The launch of Evo Plus ICL in China has been successful, with early demand exceeding expectations, contributing to the company's revenue growth.
- The company maintained spending discipline, reducing operating expenses by 18% year over year, which contributed to a return to profitability with an operating income of $8 million.
- Staar Surgical Co (STAA) faces macroeconomic and geopolitical headwinds, particularly in the Middle East and India, which impacted net sales outside China.
- The company is cautious about providing future guidance due to uncertainties in the global economic environment and potential geopolitical disruptions.
- Despite strong performance in Q1, there is uncertainty about the sustainability of this growth in subsequent quarters, particularly in China, due to historical volatility.
- Pricing pressures are evident globally, which could impact future profitability, especially as the company expands into more price-sensitive markets.
- The company is still dealing with the effects of higher-cost inventory from previous years, which may affect gross margins until the end of 2026.
Greetings, and welcome to the STAAR Surgical first quarter 2026 r esults call and webcast. (Operator Instructions)
I would now like to turn the call over to Conney Johnson, Director of Investor Relations.
Thank you, operator. Good afternoon, and thank you for joining us. On the call today are Warren Foust, Interim Co-CEO, President and Chief Operating Officer of STAAR Surgical; and Deborah Andrews, Interim Co-CEO and Chief Financial Officer of STAAR Surgical. Earlier today, we reported our first quarter of 2026 results via press release and Form 8-K. We posted our results release and shareholder letter to our investor website at investors.staar.com.
Today's call is scheduled for 1 hour and will include Q&A for publishing analysts. Webcast participants can also send questions for today's Q&A session to [email protected]. Before we get started, I want to remind you that during today's discussion, we will be making forward-looking statements. Forward-looking statements are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
